FindTrial
Sign In

Vocabria 30 mg film-coated tablets

DRUG2 trials

Sponsors

Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La C, Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La C, Inst Medecine Epidemiologie Appliquee

Conditions

HIV infectionHIV-Infected patients

Phase 3

(CAbotégravir LENacapavir DUal Long Acting). Phase II, Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA
Not yet recruitingCTIS2024-516028-33-01
Inst Medecine Epidemiologie AppliqueeHIV infection
Target: 30Updated: 2025-03-21

Phase 4

Implementation of Out-of-HOspital administration of the Long-Acting combination cabotegravir+rilpivirine as an optional therapy in HIV-Infected patients from Spain. Acceptability, appropriateness, feasibility and satisfaction. The HOLA Study.
CompletedCTIS2023-503963-41-00
Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La C, Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La CHIV-Infected patients
Start: 2023-10-05End: 2025-05-30Target: 110Updated: 2024-06-07

Related Papers

Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)—a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol
BMJ Open2025-04-012 citations